MSN Labs appoints Kalakuntla Srinivas Rao as Executive Vice President - Formulations Manufacturing Operations

Written By :  Ruchika Sharma
Published On 2025-11-01 06:32 GMT   |   Update On 2025-11-01 06:32 GMT
Advertisement

MSN Labs has appointed Kalakuntla Srinivas Rao as Executive Vice President - Formulations Manufacturing Operations.

Srinivas Rao brings with him over 26 years of rich experience in formulations manufacturing, driving operational excellence, strategic planning, and compliance management.

In a recent LinkedIn post, the company highlighted that "With his deep expertise and leadership, he will play a key role in advancing MSN’s mission of delivering high-quality, affordable medicines to patients worldwide."

Advertisement

Prior to this, Srinivas Rao held positions at renowned pharmaceutical companies, including Lupin, Novast Labs, and Dr. Reddy’s Laboratories.

Read also: SEC Recommends Phase III Trial of MSN Labs' Vibegron Against Mirabegron in Overactive Bladder

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News